(I) GRAZAX - ProInvestor

More documents

Recommendations

Info

May 2007 Direct comparison of SLIT and SCIT Curing Allergy 58 Small size studies with other products from other manufacturers give no useful information on GRAZAX ® No direct comparison of GRAZAX ® with injection-based vaccines has been performed Comparison of clinical data from multicenter studies with GRAZAX ® and ALK-Abelló injection-based vaccines suggests similar efficacy in first treatment season Reduction of symptoms Reduction of medication compared to placebo compared to placebo GRAZAX ® (GT-07) 37% 41% GRAZAX ® (GT-08) 30% 38% Alutard Injection (UK22) 29% 32%
May 2007 GRAZAX ® safety and tolerability (I) Curing Allergy 59 Grass allergen tablet doses (n=66) Placebo 25,000 SQ-T 75,000 SQ-T 300,000 SQ-T 500,000 SQ-T 1,000,000 SQ-T Treatment-related adverse events (%) 19 22 67 100 100 100 Serious or systemic adverse reactions (%) Percentages of patients experiencing treatmentrelated adverse events following administration of increasing doses of grass allergen tablets 0 0 0 0 0 0 The safety of the grass allergen tablet has been investigated at doses of up to 1,000,000 SQ-T, revealing no safety concerns The 75,000 SQ-T daily dose (GRAZAX ® ) provides the optimal benefit–risk ratio. Since the grass allergen tablet is tolerated up to 1,000,000 SQ-T, without serious or systemic adverse events, the 75,000 SQ-T daily dose (GRAZAX ® ) provides a large safety margin
Page 1 and 2:
Curing Allergy We improve quality o
Page 3 and 4:
May 2007 Table of content Curing Al
Page 5 and 6:
May 2007 What is allergy? Curing Al
Page 7 and 8: May 2007 Allergies have a significa
Page 9 and 10: May 2007 Curing Allergy 9 What is a
Page 11 and 12: May 2007 Curing Allergy 11 Immunoth
Page 13 and 14: Curing Allergy THE IMMUNOTHERAPY MA
Page 15 and 16: May 2007 The market for specific im
Page 17 and 18: Curing Allergy GRAZAX ® See more o
Page 19 and 20: May 2007 GRAZAX ® - improving qual
Page 21 and 22: May 2007 Status on GRAZAX ® - ALK-
Page 23 and 24: May 2007 Curing Allergy 23 Seasonal
Page 25 and 26: May 2007 GRAZAX ® well received in
Page 27 and 28: May 2007 GRAZAX ® is highly cost-e
Page 29 and 30: May 2007 Schering-Plough - Partner
Page 31 and 32: May 2007 ALK-Abelló and Menarini -
Page 33 and 34: May 2007 R&D Pipeline Curing Allerg
Page 35 and 36: Curing Allergy FINANCIAL HIGHLIGHTS
Page 37 and 38: May 2007 Strong underlying sales de
Page 39 and 40: May 2007 Earnings in line with expe
Page 41 and 42: May 2007 Earnings outlook for 2007
Page 43 and 44: May 2007 Forward-looking statements
Page 45 and 46: May 2007 Ongoing progress and news
Page 47 and 48: May 2007 Shareholder structure Curi
Page 49 and 50: May 2007 GRAZAX ® launch strategy
Page 51 and 52: May 2007 Market potential (I) Curin
Page 53 and 54: May 2007 GRAZAX ® - Clinical trial
Page 55 and 56: May 2007 GRAZAX ® - Clinical trial
Page 57: May 2007 Long-term efficacy of GRAZ
Page 61 and 62: May 2007 GRAZAX ® safety and toler
Page 63 and 64: May 2007 ALK-Abelló publications L
Page 65 and 66: May 2007 References Curing Allergy
Page 67 and 68: May 2007 Allergy calendar Curing Al
Page 69: May 2007 Contact Investor Relations
show all

(I) GRAZAX - ProInvestor

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?